scholarly journals Potential of Selected Trace Elements in Patients with Diabetes Mellitus

2018 ◽  
Vol 18 (3) ◽  
pp. 17-23
Author(s):  
V Ferencikova ◽  
O. Osina
Keyword(s):  
Diabetes Mellitus ◽  
Trace Elements ◽  
Blood Glucose ◽  
Essential Elements ◽  
Term Treatment ◽  
The Body ◽  
World Population ◽  
Insulin Mimetic ◽  
Regular Control ◽  
Long Term Treatment

Abstract Based on the high prevalence, diabetes mellitus (DM) is considered as a worldwide problem. More than 8.3 % of the world population is suffering from this disease. One of the causing factors of this disease can be the absence or imbalance of trace, essential elements. It can cause collapses of antioxidant defence and glucose intolerance. It plays a role in the pathogenesis and progression to diabetes mellitus. This review focuses on chromium, copper, selenium, vanadium, and zinc. Many studies deal with these elements but there is variability in opinions. Insulin-mimetic activity and ability to control the concentrations of blood glucose were confirmed. However, these effects were of more importance in patients with prediabetes. In patients with prediabetes, due to the supplementation of selected trace elements, it is possible to normalize the blood glucose level and prevent the development of diabetes mellitus. The importance of supplementation was confirmed for chromium and zinc. The supplementation of vanadium has a positive effect on the normalization of glycaemia but it is necessary to control the level as it can have toxic effects during long-term treatment. Conversely, higher copper concentrations in the body adversely affect patients and chelation therapy is needed. Selenium must be kept in the standard concentration and regular control of the concentration in the body is necessary. For this reason it is necessary to continue with analysis and the creation of new methodologies that could unify the view on the issue.

Anti-Diabetic Effect of a Flavonoid and Sitosterol - Rich Aqueous Extract ofPleurotus tuberregiumSclerotia in Alloxan-Induced Diabetic Rabbits

2019 ◽  
Vol 19 (8) ◽  
pp. 1148-1156 ◽  
Author(s):  
Ifeanacho Mercy Onuekwuzu ◽  
Ikewuchi Catherine Chidinma ◽  
Ikewuchi Jude Chigozie
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Aqueous Extract ◽  
Risk Index ◽  
Fasting Blood Glucose ◽  
Hdl Cholesterol ◽  
The Body ◽  
Atherogenic Index ◽  
Atherogenic Indices ◽  
Diabetic Rabbits

Objective:Traditionally prepared infusions and decoctions are commonly used in the management of diabetes mellitus, in southern Nigeria; one of such is the aqueous extract of the sclerotia of Pleurotus tuberregium (“usu” milk). In this study, the effects of the extract on the body weights, tissue/ organ weights, fasting blood glucose, blood/plasma lipid profiles and atherogenic indices were investigated in normal and alloxan-induced diabetic rabbits.Methods:Diabetes mellitus was induced by the injection of alloxan (120 mg/kg body weight) via the marginal ear vein. The extract was administered orally at 100, 200 and 300 mg/kg to normal and diabetic rabbits; while metformin was administered at 50 mg/kg. The crude extract was analyzed by gas chromatography, coupled to flame ionization detector.Results:Thirty-one known flavonoids were detected, consisting mainly of isoquercetin (28.5%), luteolin (24.3%), quercetin (18.8%) and kaempferol (11.3%). Sitosterol (82.0%) and stigmasterol (12.5%) were the most abundant of the seven phytosterols detected. Compared to the diabetic control, the treatment significantly (p<0.05) lowered the weights of the kidney and liver, as well as the levels of blood glucose and triglyceride, plasma VLDL, LDL and non-HDL cholesterol, atherogenic index of plasma, cardiac risk ratio, atherogenic coefficient and Castelli’s risk index II. It, however, significantly (p<0.05) increased plasma HDL cholesterol, without significantly affecting blood total cholesterol levels.Conclusion:This study showed that the extract was hypoglycemic, and improved lipid profile and atherogenic indices, thus highlighting its cardioprotective potential, thereby supporting its use in the management of diabetes mellitus.

scholarly journals Tissue-specific tregs in cancer metastasis: opportunities for precision immunotherapy

2021 ◽  
Author(s):  
Laura A. Huppert ◽  
Michael D. Green ◽  
Luke Kim ◽  
Christine Chow ◽  
Yan Leyfman ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Cancer Metastasis ◽  
Metastatic Cancer ◽  
High Volume ◽  
Therapy Resistance ◽  
Term Treatment ◽  
The Body ◽  
Tissue Specific ◽  
Tissue Repair And Regeneration ◽  
Long Term Treatment

AbstractDecades of advancements in immuno-oncology have enabled the development of current immunotherapies, which provide long-term treatment responses in certain metastatic cancer patients. However, cures remain infrequent, and most patients ultimately succumb to treatment-refractory metastatic disease. Recent insights suggest that tumors at certain organ sites exhibit distinctive response patterns to immunotherapy and can even reduce antitumor immunity within anatomically distant tumors, suggesting the activation of tissue-specific immune tolerogenic mechanisms in some cases of therapy resistance. Specialized immune cells known as regulatory T cells (Tregs) are present within all tissues in the body and coordinate the suppression of excessive immune activation to curb autoimmunity and maintain immune homeostasis. Despite the high volume of research on Tregs, the findings have failed to reconcile tissue-specific Treg functions in organs, such as tolerance, tissue repair, and regeneration, with their suppression of local and systemic tumor immunity in the context of immunotherapy resistance. To improve the understanding of how the tissue-specific functions of Tregs impact cancer immunotherapy, we review the specialized role of Tregs in clinically common and challenging organ sites of cancer metastasis, highlight research that describes Treg impacts on tissue-specific and systemic immune regulation in the context of immunotherapy, and summarize ongoing work reporting clinically feasible strategies that combine the specific targeting of Tregs with systemic cancer immunotherapy. Improved knowledge of Tregs in the framework of their tissue-specific biology and clinical sites of organ metastasis will enable more precise targeting of immunotherapy and have profound implications for treating patients with metastatic cancer.

Literature Riview : Pengaruh Terapi Relaksasi Otot Progresif Terhadap Penurunan Kadar Gula Darah Pada Pasien Diabetes Melitus

2021 ◽  
Vol 1 ◽  
pp. 921-927
Author(s):  
Oki Yanuarti ◽  
Nuniek Nizmah Fajriyah ◽  
Firman Faradisi
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Blood Sugar ◽  
Muscle Relaxation ◽  
The Body ◽  
Progressive Muscle Relaxation ◽  
Relaxation Techniques ◽  
Relaxation Therapy ◽  
High Blood Glucose ◽  
Diabetes Melitus

AbstractDiabetes melitus is a metabolic disease characterized by high blood glucose levels in the body, caused by abnormalitized in insulin secretion. One of the non-pharmacological method to reduce blood sugar level is progressive muscle relaxation therapy. This study aims to identify the effect of progressive muscle relaxation techniques in lowering blood sugar. A literature review of studies of progressive muscle relaxation therapy in reducing blood sugar publishedin 2011-2020 was conducted. The average number of respondents was 26 male and female responden with and average age of 55-60. The results showed that progressive muscle relaxation therapy was able to control blood glucose among diabetic. This study concludes that progressive muscle relaxation therapy effectively reduce blood sugar levels in patients with diabetes melitus. The findings suggest that progressive muscle relaxation therapy can be used as non-pharmacological therapy to lower blood sugar levels.Keywords: Diabetes mellitus; Progressive muscle relaxation AbstrakDiabetes melitus merupakan suatu penyakit degeneratif yang bermasalah pada sistem metabolik ditandai dengan meningkatnya kadar gula darah dalam tubuh dan disebabkan karena kelainan sekresi insulin. Pada pasien diabetes melitus akan mengalami peningkatan kadar gula darah dalam tubuh, salah satu cara non farmakologis yang dapat dilakukan untuk menurunkan kadar gula darah pada pasien diabetes melitus yaitu dengan terapi relaksasi otot progresif. Tujuan dari Karya Tulis Ilmiah ini yaitu untuk mengetahui gambaran dari pengaruh teknik relaksasi otot progresif terhadap penurunan kadar gula darah pada pasien diabetes melitus. Metode yang dilakukan dengan mencari tiga jurnal penelitian tentang pengaruh terapi relaksasi otot progresif terhadap penurunan kadar gula darah pada pasien diabetes melitus terbit pada tahun 2011-2020. Hasil analisa karakteristik responden dari ketiga jurnal menunjukan jumlah responden rata-rata 26 responden laki-laki dan perempuan dengan usia rata-rata 55-60 tahun. Hasil yang didapatkan setelah dilakukan terapi relaksasi otot progresif kadar gula darah pasien menjadi terkontrol. Simpulan dari karya tulis ilmiah ini yaitu terapi relaksasi otot progresif efektif terhadap penurunan kadar gula darah pada pasien diabetes melitus. Saran bagi perawat atau penderita diabetes melitus terapi relaksasi otot progresif dapat digunakan sebagai terapi non farmakologis untuk menurunkan kadar gula darah pada pasien diabetes melitus. Kata kunci: Diabetes mellitus; Relaksasi Otot Progresif

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

1994 ◽  
Vol 131 (1) ◽  
pp. 20-26 ◽  
Author(s):  
Josef Marek ◽  
Václav Hána ◽  
Michal Kršek ◽  
Vlasta Justová ◽  
France Catus ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Slow Release ◽  
Serum Levels ◽  
Term Treatment ◽  
Somatostatin Analogue ◽  
Tumour Mass ◽  
Long Term Treatment ◽  
Active Acromegaly ◽  
One Year

Marek J, Hána V. Kršek M. Justová V, Catus F, Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 1994;131:20–6. ISSN 0804–4643 Thirteen patients with active acromegaly despite previous surgery were treated with 30 mg lanreotide im twice a month for 9 months. In 10 subjects the treatment continued to 19 months. GH serum levels of all patients decreased significantly from an initial value of 32.0 (29.4) μg/l [median (standard error of median)] to 10.0 (3.6) and 19.1 (5.7) after 3 and 9 months of treatment, respectively. In the 10 patients with the treatment longer than one year the decrease in GH was from 46.8 (29.4) μg/l to 12.5 (5.0) and 16.1 (5.3) after 13 and 19 months, respectively. IGF-I serum levels decreased significantly from 1193 (73)μg/l to 782 (99) and 621 (103) after 3 and 9 months, respectively, and were normalized in 3 patients. In the 10 patients treated for longer than one year, levels decreased significantly from 1318 (74)μg/l to 653 (170) and 742 (180) after 13 and 19 months, respectively. IGF BP-3 levels were reduced to the normal range in 6 patients and decreased from 8.7 (1.5)mg/l to 6.4 (0.8) and to 5.4 (1.0) after 3 and 9 months, respectively. In the patients with the 19 months treatment the decrease was from 9.3 (1.6) mg/l to 3.9 (0.9) and 4.8 (0.9) after 13 and 19 months, respectively. The IGF BP-3 to IFG I ratio increased in 7 patients. This elevation significantly correlated with the decrease in bioassayable somatomedin. Prolactin serum levels fell in all patients with increased prolactin secretion. Testosterone plasma levels increased in 4 out of 5 men without replacement therapy. Clinical improvement was observed in all patients. A reduction of tumour mass was observed in five patients and complete disappearance of the tumour in one subject. All patients complained of mild abdominal pain and softened stools for several days following the injections. However, these side effects never required interruption of treatment. Asymptomatic microlithiasis was seen in only one patient after 13 months, which led to treatment being suspended for a period of 3 months after which it was resumed. Fasting serum insulin and insulin area under the curve (AUC) after oral glucose tolerance test (OGTT) fell in all patients. Fasting blood glucose, fructosamine and glucose AUC after OGTT slightly increased during the treatment, but all blood glucose levels (fasting and during OGTT) remained within normal ranges. Lanreotide appears to be a safe and effective treatment in patients with active acromegaly unresolved by surgery. The long-acting formulation avoids the drawbacks associated with either repeated daily injections or continuous infusions of somatostatin analogues. Josef Marek, Third Department of Medicine, Charles University, U nemocnice 1, 128 21 Praha 2, The Czech Republic

Long-Term Treatment with Pivmecillinam in Patients with Recurrent Bacteriuria

1982 ◽  
Vol 10 (3) ◽  
pp. 179-182
Author(s):  
B Bresky ◽  
K Lincoln
Keyword(s):  
Escherichia Coli ◽  
Adverse Effect ◽  
Renal Function ◽  
Term Treatment ◽  
The Body ◽  
End Of Treatment ◽  
Long Term Treatment ◽  
Tract Infections

Thirty out-patients with chronic recurrent urinary tract infections, who had failed to respond to 10 days treatment with either pivmecillinam and/or amoxycillin, received a 3-month course of pivmecillinam at a dose of 200 mg, three times daily. Twenty-seven patients had bacteriuria due to Enterobacteriaceae, mainly Escherichia coli, sensitive to mecillinam in vitro. Pivmecillinam eradicated all the initial urinary pathogens. Reinfections occurred during treatment in three patients, who remained asymptomatic. Four subjects complained of gastro-intestinal side-effects, and therapy was withdrawn in three instances. Another three patients described unusual adverse events towards the end of the course of treatment, described as an odd sensation in the body and a desire for salt. The sensation disappeared a few days after the end of treatment. Treatment with pivmecillinam had no adverse effect on haematopoietic, hepatic or renal function.

scholarly journals Meningkatkan Kesehatan Mental Penderita Diabetes Melitus di Komunitas dengan Kegiatan Kelompok Swabantu (Self Help Group)

2019 ◽  
Vol 1 (2) ◽  
pp. 92
Author(s):  
Tesaviani Kusumastiwi ◽  
Lilis Suryani ◽  
Denny Anggoro P
Keyword(s):  
Diabetes Mellitus ◽  
Mental Health Problems ◽  
Clinical Symptoms ◽  
Term Treatment ◽  
Self Help ◽  
Long Term Treatment ◽  
Patients With Diabetes ◽  
Self Help Groups ◽  
Self Help Group ◽  
Diabetes Melitus

Diabetes melitus merupakan penyakit metabolik yang memiliki prevalensi yang cukup tinggi di Indonesia. Penanganan jangka panjang pada penyakit ini dapat memberikan beban baik fisik maupun mental pada penderitanya. Munculnya masalah kesehatan mental pada pasien diabetes melitus akan memperburuk prognosis pasien. Penanganan holistik baik fisik dan mental diharapkan dapat dilakukan pasien diabetes melitus, salah satunya melalui kelompok swabantu (self help group) yakni kelompok yang terdiri dari para penderita diabetes melitus yang saling berbagi permasalahan dan memberikan dukungan satu sama lain. Program pengabdian masyarakat kelompok swabantu  penderita diabetes mellitus dilaksanakan di Desa Bogoran, Trirenggo, Bantul. Kegiatan swabantu berisi tentang sharing dari masing-masing penderita yang dipantau/dimonitor oleh dokter ahli jiwa. Pada kelompok swabantu di Desa Bogoran, Trirenggo, Bantul ditemukan komorbiditas gejala klinis depresi dan cemas pada penderita diabetes. Beberapa permasalahan yang dialami oleh para penderita adalah manajemen stres, gangguan tidur, kepatuhan minum obat, ketakutan akan komplikasi dan penyesuaian gaya hidup. Kegiatan kelompok swabantu selain dapat membantu para penderita diabetes dalam menangani permasalahan yang dihadapi terkait dengan diabetes melitus, juga dapat memberikan rasa kebersamaan dan saling menguatkan antar penderita diabetes.Kata kunci: diabetes melitus, kelompok swabantu, kesehatan mentalAbstractDiabetes mellitus is a metabolic disease that has a high prevalence in Indonesia. Long-term treatment of this disease can provide physical and mental burden on the sufferer. The emergence of mental health problems in patients with diabetes mellitus will worsen the patient's prognosis. Holistic handling both physically and mentally is expected to be carried out by patients with diabetes mellitus, one is through self-help groups (self-help group), which is a group consisting of people with diabetes mellitus who share problems and provide support for each other. The community service program for self-help groups with diabetes mellitus was carried out in Bogoran Village, Trirenggo, Bantul. Self-help activities are about sharing from each sufferer who is monitored by a psychiatrist. In the self-help group in the Bogoran Bantul area, comorbid clinical symptoms of depression and anxiety were found in diabetics. Some of the problems experienced by sufferers are stress management, sleep disorders, compliance with medication, fear of complications and lifestyle adjustments. Self-help group activities besides being able to help diabetics in dealing with problems faced with diabetes mellitus, they can also provide a sense of togetherness and mutual support among diabetics.

Free fatty acids normalize a rosiglitazone-induced visfatin release

2006 ◽  
Vol 291 (5) ◽  
pp. E885-E890 ◽  
Author(s):  
Dominik G. Haider ◽  
Friedrich Mittermayer ◽  
Georg Schaller ◽  
Michaela Artwohl ◽  
Sabina M. Baumgartner-Parzer ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Free Fatty Acids ◽  
Term Treatment ◽  
Double Blind ◽  
Lipid Infusion ◽  
Major Mechanism ◽  
Insulin Mimetic ◽  
Long Term Treatment ◽  
Plasma Ffa

The detrimental effect of elevated free fatty acids (FFAs) on insulin sensitivity can be improved by thiazolidinediones (TZDs) in patients with type 2 diabetes mellitus. It is unknown whether this salutary action of TZD is associated with altered release of the insulin-mimetic adipocytokine visfatin. In this study, we investigated whether visfatin concentrations are altered by FFA and TZD treatment. In a randomized, double-blind, placebo-controlled, parallel-group study 16 healthy volunteers received an infusion of triglycerides/heparin to increase plasma FFA after 3 wk of treatment with rosiglitazone (8 mg/day, n = 8) or placebo ( n = 8), and circulating plasma visfatin was measured. As a corollary, human adipocytes were incubated with synthetic fatty acids and rosiglitazone to assess visfatin release in vitro. The results were that rosiglitazone treatment increased systemic plasma visfatin concentrations from 0.6 ± 0.1 to 1.7 ± 0.2 ng/ml ( P < 0.01). Lipid infusion caused a marked elevation of plasma FFA but had no effect on circulating visfatin in controls. In contrast, elevated visfatin concentrations in subjects receiving rosiglitazone were normalized by lipid infusion. In isolated adipocytes, visfatin was released into supernatant medium by acute addition and long-term treatment of rosiglitazone. This secretion was blocked by synthetic fatty acids and by inhibition of phosphatidylinositol 3-kinase or Akt. In conclusion, release of the insulin-mimetic visfatin may represent a major mechanism of metabolic TZD action. The presence of FFA antagonizes this action, which may have implications for visfatin bioactivity.

Sign in / Sign up

Export Citation Format

Share Document